Hi Jane-
It's a fantastic trial. Depending on which of the 3
open arms he is randomly assigned to, he will get:
• ADT alone, which is the current standard of care
• ADT with radiotherapy, which would de-bulk the primary tumor
• ADT+Xtandi+Zytiga, which is a "cocktail" of the best currently approved hormone therapies
The arms that are closed to recruitment include combinations with Zometa (to preserve bone during ADT), Taxotere (chemo), and Celebrex (an anti-inflammatory).
Last year, it was discovered that Taxotere can significantly extend life if given while the cancer is still hormone sensitive and there are
extensive mets. The benefit is less if there are few mets - I don't know exactly what you mean by "small amounts." So by entering the trial, you would be giving up this opportunity if it is one.
This trial will make a huge contribution to our knowledge of how best to treat metastatic PC, and a lot of people in the future will benefit from his participation.
Here's a link:
www.cancer.gov/clinicaltrials/search/view?cdrid=455008&version=HealthProfessional- Allen